Rubric Capital Management (New York)’s ANI Pharmaceuticals ANIP Stock Holding History

Rubric Capital Management (New York)’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.4M	Buy	+258,131	New	+$20.7M	0.2%	70
2025 Q4	–	Sell	-343,414	Closed	-$31.5M	–	78
2025 Q3	$31.5M	Buy	343,414 +85,745	+33%	+$6.99M	0.35%	48
2025 Q2	$16.8M	Buy	257,669 +200,998	+355%	+$13.1M	0.25%	56
2025 Q1	$3.79M	Hold	56,671	–	–	0.07%	59
2024 Q4	$3.13M	Hold	56,671	–	–	0.04%	65
2024 Q3	$3.38M	Sell	56,671 -547,129	-91%	-$33.4M	0.06%	59
2024 Q2	$38.4M	Sell	603,800 -354,733	-37%	-$23M	1.01%	38
2024 Q1	$66.3M	Sell	958,533 -166,467	-15%	-$10M	1.96%	18
2023 Q4	$62M	Buy	1,125,000 +277,989	+33%	+$15.3M	1.29%	12
2023 Q3	$49.2M	Hold	847,011	–	–	1.84%	19
2023 Q2	$45.6M	Buy	847,011 +198,970	+31%	+$8.82M	1.95%	22
2023 Q1	$25.7M	Buy	648,041 +271,909	+72%	+$11.5M	0.67%	37
2022 Q4	$15.1M	Buy	376,132 +89,086	+31%	+$3.35M	0.66%	44
2022 Q3	$9.23M	Buy	287,046 +204,602	+248%	+$7M	0.46%	46
2022 Q2	$2.45M	Buy	+82,444	New	+$2.38M	0.13%	75
2022 Q1	–	Sell	-307,557	Closed	-$14.2M	–	73
2021 Q4	$14.2M	Buy	+307,557	New	+$13.2M	0.67%	42

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rubric Capital Management (New York)'s ANIP Position: Q2 2026 in Review

Rubric Capital Management (New York) opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 258,131 shares worth $21.4M. The stake represents 0.2% of the portfolio and ranks #70 among its holdings. This is a return to the name: Rubric Capital Management (New York) previously reported a position in ANIP as recently as Q3 2025.

Rubric Capital Management (New York) first reported a position in ANIP in Q4 2021 and has held it in 16 quarters since. The position peaked at $66.3M in Q1 2024. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Rubric Capital Management (New York) held 258,131 shares of ANI Pharmaceuticals worth $21.4M as of Q2 2026.
ANI Pharmaceuticals was a new Rubric Capital Management (New York) position in Q2 2026.
ANI Pharmaceuticals made up 0.2% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #70 holding.
Rubric Capital Management (New York) first reported a position in ANI Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
Rubric Capital Management (New York)'s ANI Pharmaceuticals position peaked at $66.3M in Q1 2024.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.